The bellwether biotech Biogen has wooed a top investigator from Pfizer to take over as head of R&D. The company reported this morning that Michael Ehlers, who had been running the neuroscience and pain research operations at Pfizer, is stepping into the role of executive vice president, R&D.
Ehlers, a former Howard Hughes Medical Institute investigator at Duke, had specialized in neuronal organelles and the trafficking of neurotransmitter receptors.
His background in the Cambridge/Boston hub working for Pfizer should prove to be a nice fit with Biogen, which has carved out an ambitious set of leading–and notably risky–programs on Alzheimer’s and other tough diseases.
Biogen’s former R&D chief, Doug Williams, left last summer to run a biotech startup. And Ehlers is benefiting once again from the migration of senior biotech execs into startup roles. He was promoted at Pfizer close to a year ago after José-Carlos Gutiérrez-Ramos left his prominent job as head of BioTherapeutics R&D in Cambridge, MA, to take the reins at Synlogic.
Just last fall Biogen underwent a wrenching reorganization, laying off 850 staffers and narrowing its R&D focus after the numbers on its MS operations disappointed Wall Street. But it circled the wagons in Alzheimer’s, focusing on aducanumab, a Phase III beta-amyloid antibody that has produced mixed but encouraging early-stage data.
Biogen is also collaborating with Isis Pharmaceuticals ($ISIS) on spinal muscular atrophy, a next-gen MS drug in midstage development, a Phase III program for inflammatory bowel disease and a late-stage treatment for trigeminal neuralgia, a rare disease.
“Biogen is a recognized leader in applying the highest quality science to critical health issues in neurodegenerative and rare diseases,” said Ehlers.
By John Carroll
Source: Fierce Biotech
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
